№ files_lp_4_process_2_38042
File format: docx
Character count: 38978
File size: 149 KB
A standardized template for assessing the benefit-risk profile of nucleic acid vaccines, designed for use by vaccine developers and regulatory authorities in evaluating safety and efficacy across diverse populations.
Year:
2021
Region / City:
Global
Topic:
Vaccine Benefit-Risk Assessment
Document Type:
Standardized Template
Organization / Institution:
Brighton Collaboration
Author:
Brighton Collaboration Working Groups
Target Audience:
Vaccine developers, regulatory authorities, public health professionals
Period of validity:
Indefinite
Date of approval:
N/A
Date of changes:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019
Dates:
17–18 September 2019
Location:
Geneva, Switzerland
Venue:
Best Western Chavannes De Bogis, Chemin des Champs-Blancs 70B, 1279 Chavannes-de-Bogis
Document Type:
Meeting minutes
Organising Body:
CIOMS (Council for International Organizations of Medical Sciences)
Working Group:
CIOMS Working Group XII
Subject:
Benefit-risk balance assessment for medicinal products
Related Guidance:
CIOMS IV (published 1998)
Chair:
Lembit Rägo
President (Opening):
Hervé Le Louët
Rapporteur:
Panos Tsintis
Participants:
Representatives from regulatory authorities, industry, academia, and international organizations
Main Topics:
Update of CIOMS IV guidance; qualitative and quantitative benefit-risk assessment; regulatory perspectives; industry perspectives; patient preferences; real-world evidence; post-marketing evaluation; risk communication; lifecycle approach to benefit-risk
Meeting Outcome:
Agreement on objectives, drafting structure, subgroup formation, and planning of future work for new CIOMS XII guidance
Year:
2025
Region / city:
Global
Topic:
Vaccine Policy, Maternal Health, Group B Streptococcus
Document type:
WHO Guidance
Institution:
World Health Organization (WHO)
Author:
WHO ECVP
Target audience:
Policymakers, Vaccine Developers, Public Health Authorities
Period of validity:
Ongoing
Approval date:
March 11, 2025
Date of changes:
Not specified
Year:
2024
Region / city:
Global
Topic:
COVID-19 Vaccines
Document type:
Report
Author:
World Health Organization (WHO)
Target audience:
Health professionals, regulatory authorities
Approval date:
16 January 2024
Modification date:
N/A
Contextual description:
A report listing COVID-19 vaccines evaluated under the WHO EUL/PQ process, including details on manufacturers, vaccine types, shelf lives, and approval dates.
Year:
2026
Jurisdiction:
Victoria, Australia
Document type:
Report form
Subject:
Vaccine cold chain breach reporting
Issuing authority:
Department of Health, Victorian Government
Program:
Immunisation Program
Applicable vaccines:
Government funded vaccines and immunisation products
Target users:
Immunisation providers
Scope:
Cold chain breach events excluding delivery incidents
Temperature range reference:
+2°C to +8°C
Reporting method:
Email submission to Immunisation Program
Publication date:
January 2026
Publisher:
State of Victoria, Australia
Copyright holder:
Department of Health, Victoria
Note:
Year
Region / City:
Alabama
Theme:
Vaccine management, immunization program
Document Type:
Vaccine management plan
Organization / Institution:
Alabama Department of Public Health (ADPH)
Author:
Alabama Department of Public Health (ADPH)
Target Audience:
VFC providers, immunization staff
Effective Period:
Ongoing
Year:
2024
Region / City:
Victoria, Australia
Topic:
Immunisation
Document Type:
Official Information
Author:
Department of Health, State of Victoria
Target Audience:
Healthcare professionals, parents, and individuals requiring immunisation information
Period of Validity:
Not specified
Approval Date:
August 2024
Date of Changes:
Not specified
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Region / city:
Victoria, Australia
Subject:
Immunisation, Vaccines
Document type:
Health guideline
Organ / institution:
Department of Health and Human Services, Victorian Government
Author:
Victorian Government
Target audience:
Healthcare professionals, general public, parents, caregivers
Period of validity:
Until 2025
Approval date:
July 2025
Date of amendments:
Not specified
Year:
2023
Region / city:
Australia
Topic:
COVID-19 vaccines
Document type:
Clinical guidance
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, general public
Period of validity:
Ongoing
Approval date:
October 2023
Date of changes:
Multiple updates since February 2021
Year:
2025
Region / City:
Northern Ireland
Topic:
COVID-19 vaccination, mRNA vaccines
Document Type:
Protocol
Organization / Institution:
Strategic Planning and Performance Group (SPPG), Public Health Agency (PHA)
Author:
Dr. Louise Herron, Mrs. Deirdre Ward, Mrs. Kathryn Turner
Target Audience:
Healthcare professionals administering COVID-19 mRNA vaccines
Period of Validity:
3 April 2025 to 30 June 2025
Approval Date:
3 April 2025
Note:
Change History
Version 1.0:
New national protocol for COVID-19 vaccines (adults) - 5 April 2024
Version 2.0:
Updated to reflect change in vaccine antigenic content - 16 September 2024
Version 3.0:
Updated eligibility criteria for Spring 2025 - 6 March 2025
Year:
2025
Region / City:
Wisconsin
Theme:
Public Health, Vaccination Programs
Document Type:
Provider Agreement
Organization:
Department of Health Services, Division of Public Health
Author:
Department of Health Services
Target Audience:
Health Care Providers, Medical Directors
Period of Validity:
Annual Enrollment
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2023
Region / City:
Europe
Topic:
Access to medicines, hormones, healthcare for trans and gender-diverse people
Document Type:
Analytical study
Organ / Institution:
United Nations Office of the High Commissioner for Human Rights
Author:
Transgender Europe (TGEU), ILGA-Europe
Target Audience:
Policymakers, Human Rights Advocates, Health Professionals
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Year:
2023
Region / city:
Australia
Topic:
HPV vaccination recommendations
Document type:
Advisory report
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, policy makers, the general public
Validity period:
Ongoing
Approval date:
30 January 2023
Amendment date:
30 January 2023
Year:
2020
Region / city:
Global
Topic:
COVID-19, Clinical Trials, Remote Monitoring, Data Verification
Document Type:
Guide/Playbook
Organization:
European Medicines Agency (EMA)
Author:
Not specified
Target Audience:
Clinical Trial Monitors, Healthcare Professionals, Regulatory Agencies
Period of Action:
Ongoing during COVID-19 pandemic
Approval Date:
July 2020
Date of Changes:
Not specified
Live Attenuated Vaccines: Avoid Use In Those Who Are Clinically Immunosuppressed, Including Neonates
Year:
2016
Region / City:
Wales
Topic:
Vaccination, Immunosuppression
Document Type:
Medical/Health Advisory
Organization:
NHS Wales
Author:
Dr Chris Jones
Target Audience:
Healthcare professionals, General practitioners, Paediatricians, Oncologists, Rheumatologists, Immunologists, Nurses, Pharmacists, Medical Directors
Period of Validity:
Not specified
Approval Date:
4 May 2016
Modification Date:
Not specified
Contextual Description:
Medical advisory document warning healthcare professionals about the risks of live attenuated vaccines for immunosuppressed individuals, especially neonates and elderly patients.
Year:
2021
Region / City:
Global
Subject:
Procurement
Document Type:
Bidding Document
Organization:
The World Bank
Author:
The World Bank
Target Audience:
Bidders, Contractors, Procurement Officers
Period of Validity:
N/A
Approval Date:
June 2021
Date of Changes:
June 2021
Note:
Year
Document Type:
Permit Application
Agency / Institution:
City of Brighton
Target Audience:
Contractors, City of Brighton Public Works
Author:
Patrick Hopkinson
Publication date:
December 2025
Type of document:
Safeguarding Adult Review
Region:
Brighton and Hove
Themes:
Adult safeguarding, multi-agency working, substance use, self-neglect, exploitation
Target audience:
Professionals working in adult safeguarding, social care, health services
Date of approval:
December 2025
Date of changes:
N/A
Year:
2024
Date:
8 March 2024
Day:
Friday
Venue:
AMEX Brighton
City:
Brighton
Region:
Kent, Surrey and Sussex
Type of document:
Conference agenda
Event:
KSS Annual Educator Conference
Organising body:
KSS
Key roles:
KSS Postgraduate Dean; Regional Postgraduate Dean; Primary Care Dean; Deputy Dean for Secondary Care; Associate Dean
Speakers:
Jo Szram; Paul Sadler; Chris Warwick; Sarah Rafferty; Subir Mukherjee; Sheona McLeod; Rob Galloway; Kevin Davis
Programme elements:
Registration; keynote sessions; workshops; networking; closing remarks
Target audience:
Educators and training staff
Programme structure:
Plenary sessions and rotating workshops
Note:
Agenda subject to change
Organisation:
Brighton & Hove City Council
Job title:
Director Finance and Property (S151)
Reports to:
Chief Executive
Directorate:
Central Hub
Division:
Finance and Property
Job identification number (JIN):
4424
Role type:
Service Director / Statutory Officer (S151)
Governance responsibility:
Extended Corporate Leadership Team
Key statutory function:
Section 151 Officer
Primary responsibilities:
Financial strategy, budget oversight, property portfolio management, statutory financial compliance
Committee accountability:
Audit, Standards & General Purposes Committee
Professional requirements:
CIPFA, ACCA, CIMA or equivalent finance qualification
Sector:
Local government
Location:
Brighton and Hove, United Kingdom
Health and safety requirement:
IOSH for Executives and Directors training